Following the release of the CREST-UK retrospective chart study results, we interviewed Dr Priyanka Mehta, lead investigator of the RWE study. Watch as she gives her thoughts on the rationale behind the study, and the clinical impact it can have on UK adults with AML-MRC and t-AML.
This site is intended for United Kingdom/Ireland healthcare professionals
Filter
-
5 mins
Vyxeos Liposomal UK RWE: CREST-UKTopics
Learning material Real-world Data Safety Vyxeos Liposomal Data
UK-VYX-2200183 | December 2022
- DISCOVER THE CREST-UK RWE STUDY: ASH 2022
Explore the latest CREST-UK RWE study that was accepted at ASH 2022. This retrospective study of 147 UK patients evaluated the efficacy and safety of Vyxeos Liposomal in routine clinical practice.
UK-VYX-2200182 | December 2022
- Vyxeos Liposomal: An overview of real-world evidence from five European studies
Key data for Vyxeos Liposomal from cohorts in England, CREST-UK, France, Italy and Germany in the context of Study 301 results.
Topics
Real-world Data Safety Vyxeos Liposomal Data
UK-VYX-2300002 | February 2023
-
3 mins
Vyxeos Liposomal: Licence and Indication cardAll the details you need on the indication and reimbursement status of Vyxeos Liposomal are available at a glance in this card.
Topics
Practicalities
UK-VYX-2100126 | September 2022
-
1 min
The American Society of Hematology (ASH) Guidelines: A Summary by Dr Priyanka MehtaA brief summary from Dr Priyanka Mehta of the latest American Society of Hematology (ASH) recommendations for the treatment of older patients with AML.
Topics
Practicalities Safety
UK-VYX-2200089 | June 2022
-
3 mins
Selecting the Right Treatment for Your Patient: Balancing the Needs for Cytogenetic Testing With the Urgency of Treatment InitiationDr Erin Hurst and Dr Priyanka Mehta discuss striking the right balance between using cytogenetic testing to inform treatment decisions in patients with acute myeloid leukaemia and initiating treatment as soon as possible, and how to utilise the time between cytogenetic test and results effectively.
Topics
Cytogenetics
UK-VYX-2200090 | June 2022
-
3 mins
A New Era in Acute Myeloid Leukaemia (AML): The Importance of Cytogenetic TestingWatch as Prof. Nigel Russell talks about the importance of cytogenetic testing in treatment decision-making for patients with AML.
Topics
AML Landscape Cytogenetics
UK-VYX-2200091 | June 2022
-
10 mins
Integrating Cytogenetics in Acute Myeloid Leukaemia (AML) Decision-Making: A Case StudyDr Priyanka Mehta, Consultant Haematologist, and Dr Rachel Protheroe, Haematologist and Transplant Consultant, both from the University Hospitals Bristol discuss their approach in treating patients with AML and how cytogenetic testing has transformed this approach. While Consultant Clinical Scientist of the Bristol Genetics Laboratory, Dr Chris Wragg, gives an overview of the cytogenetic testing process in his lab and the changes he has implemented so results can be made available in a timely manner.
Topics
Cytogenetics
UK-VYX-2200092 | June 2022
-
8 mins
Vyxeos Liposomal: Practical InformationThis leaflet contains useful information on the indication and reimbursement status of Vyxeos Liposomal, as well as detailed instructions on how to prepare, store and administer the treatment.
Topics
Practicalities
UK-VYX-2100129 | September 2022
-
5 mins
Preparation and HandlingLearn how to prepare and store the Vyxeos Liposomal infusion with this video.
Topics
Practicalities
UK-VYX-2200093 | June 2022
-
10 mins
Vyxeos Liposomal: Patient InformationA simple guide to help patients understand everything they need to know about their treatment with Vyxeos Liposomal.
Topics
Practicalities Safety Vyxeos Liposomal Data
UK-VYX-2200146 l October 2022
-
4 mins
Mode of Action (MoA) and Phase III DataLearn about the MoA of Vyxeos Liposomal to see how it can benefit patients with t-AML and AML-MRC.
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2300005 | March 2023